TD Cowen raised the firm’s price target on BioLife Solutions (BLFS) to $31 from $28 and keeps a Buy rating on the shares. The firm said core revenues of $27M beat consensus driven by Cell Processing strength. Management feels the macro environment is largely normalized driving this segment with 80% of revenues coming from top-20 pharma.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS:
- BioLife Solutions Reports Strong Q3 2024 Results
- BioLife Solutions lowers FY24 revenue view to $98.0M-$100.0M from $99.0M-$101.0M
- BioLife Solutions reports Q3 ContOps GAAP EPS (4c), consensus (9c)
- BLFS Earnings this Week: How Will it Perform?
- Disney upgraded, JPMorgan downgraded: Wall Street’s top analyst calls